HUMANA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.4 SEK | -0.15% |
|
+2.53% | +15.10% |
| May. 27 | Humana Unit Seeks Compensation for Financial Damage over Permit Revocation | MT |
| May. 23 | Humana to Sell Elderly Care Units in Finland for EUR25 Million | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its low valuation, with P/E ratio at 7.57 and 6.73 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.62 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company sustains low margins.
- The group shows a rather high level of debt in proportion to its EBITDA.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +15.10% | 147M | B | ||
| -23.43% | 2.23B | B- | ||
| +14.42% | 1.63B | - | C+ | |
| +15.29% | 1.3B | B | ||
| -34.18% | 1.23B | - | ||
| +24.98% | 768M | - | B | |
| -12.73% | 431M | B- | ||
| +186.13% | 363M | - | D+ | |
| -9.10% | 326M | - | - | |
| +25.92% | 78.76M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HUM Stock
- Ratings Humana AB
